<DOC>
	<DOCNO>NCT02478645</DOCNO>
	<brief_summary>Many patient receive opioid base analgesia gynecologic laparoscopic surgery experience postoperative nausea vomiting ( PONV ) despite prophylaxis treatment HT3 receptor antagonist . Although high dose ramosetron cause adverse effect headache dizziness , minimal effective dose ramosetron high-risk patient unknown . The aim study determine effective dose ramosetron prophylaxis PONV high-risk patient receive intravenous opioid-based patient-controlled analgesia gynecological laparoscopic surgery .</brief_summary>
	<brief_title>Dose-ranging Study Ramosetron Prevention Nausea Vomiting After Gynecologic Laparoscopic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>patient 20 70 age ASA physical status ⅠⅡ patient schedule elective gynecological laparoscopic surgery . hepatorenal disease BMI &gt; 35 kg/m2 allergy ramosetron gastrointestinal disease vomit within 24h administration antiemetic opioids within 24h QT prolongation ( QTc &gt; 440ms ) pregnant problem communication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>